NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma |
|
|
| Recruiting | 2 | 40 | US | Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc. | Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma | 10/24 | 04/25 | | |
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma |
|
|
| Active, not recruiting | 2 | 101 | US | Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) | CARGO Therapeutics | Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | 09/25 | 12/26 | | |
